Patent · US Active

Gigaxonin fusion protein and methods for treating giant axonal neuropathy

US9221890B2 · kind B2 · utility

0Cited by

1References

5Claims

0Family size

Assignee

INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION · US

Inventors

R. Mark Payne · Zionsville, US
Clifford M. Babbey · Indianapolis, US
Kyle B. Martin · Miami, US
Samuel M. Beard · Indianapolis, US

Key dates

Filing date	Oct 25, 2012
Grant date	Dec 29, 2015
Priority date	—
Expiry date	Oct 25, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates generally to fusion proteins including gigaxonin coupled to a cell penetrant peptide. These fusion proteins can be used to treat GAN in a subject in need thereof. Administration of the fusion proteins allows for control of at least one of Galectin-1 (GAL-1) levels and phosphorylated vimentin protein levels, thereby mediating aggregation of vimentin and the formation of vimentin-free zones in cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.